Wednesday Lecture Series: "Pediatric Bipolar Disorder: Treating the Irrational with the Rationale"
If a child’s mood interferes with his or her day-to-day life that causes significant disruption in school, at home with family, friends, and his/her community it is certainly important and key to take notice and seek medical/psychological treatment immediately. When left untreated, mood disorders can have devastating consequences, including school dropout, drug abuse and suicide.
The goal of early identification and treatment is first and foremost. However, there is confusion and uncertainty surrounding diagnosis & diagnostics; which type (s) of mood disorder presented? What exactly are we treating? The variable developmental expression of mania and its symptomatic overlap (comorbidities) with attention-deficit hyperactivity disorder (ADHD), Oppositional Defiant Disorder (ODD), Conduct Disorder, Anxiety Disorder, and Mood Disorders is daunting at a minimum.
This lecture will review defining Pediatric Mood Disorders, Identification of Pediatric Bipolar Disorder, Treatment and Current Therapies and are they working? Presentation of new and current research and an overview of really cool future directions will also be included and presented.
This lecture is intended for physicians, nurses, psychologists, social workers, counselors and other mental health professionals.
1. Define pediatric mood disorders.
2. List the criteria for bipolar disorder and describe three reasons why it is frequently misdiagnosed.
3. Recognize and predict the challenges associated with child psychiatry and comorbidity.
Pablo H. Goldberg, MD is an Associate Professor at Columbia University, Columbia University Medical Center. He is currently Medical Director of the Pediatric Anxiety and Mood Research Clinic (PAMRC) at the Columbia University Medical Center (CUMC), NY State Psychiatric Institute, Department of Psychiatry: Division of Child and Adolescent Psychiatry. Dr. Pablo Goldberg supervises medical care, research protocols, and pharmacological treatment at CU‐ PAMRC. Dr. Goldberg has coordinated and provided noteworthy clinical care within the Child Psychopharmacological Research protocols at the NY State Psychiatric Institute, Division of Child and Adolescent Psychiatry. Currently, working on studies involving Child and Adolescent Anxiety, particularly OCD and Mood Disorders. In previous years: ADHD, Adolescent Suicide with the Division of Child Psychiatry, Adult Mood Disorders and Suicide with the Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, Columbia Presbyterian Medical Center. Dr. Goldberg has served as the Director of the Child Psychiatry Emergency Services at Columbia University Medical Center from 2009‐2011. Dr. Goldberg has demonstrated excellence as a clinician, educator, scholar, and administrator at the Columbia University Medical Center, NY State Psychiatric Institute, Department of Psychiatry: Division of Child and Adolescent Psychiatry. He has been on the National stage and has lectured on the International stage. Dr. Goldberg is an educator, clinician, and has been a visible role model to residents, fellows, administrative staff, and senior faculty. Dr. Goldberg is board certified in both adult and child psychiatry. Pablo H. Goldberg, M.D. has published two (2) chapters (July, 2015), Treatments of Pediatric Bipolar Disorder (Senior Author) & Treatments of Pediatric Depression in “A Guide To Treatments That Work” (Fourth ed.). Oxford: Oxford University Press. Editor: Peter E. Nathan and Jack M. Gorman. He has also published in scientific renowned peer‐reviewed journals, and is an active member of the American Psychiatric Association (at the level of “Fellow”), American Association of Child and Adolescent Psychiatry, and the American Medical Association.
Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers and speakers have been asked to disclose any relationship he /she or their spouse/partner has with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt Health System, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.
Pablo H. Goldberg, M.D. reports having received research funding from NIH, NICHD, Eli Lilly and Pfizer, during the past 12 months. Additionally, he receives royalties from publications from APPI and Oxford Press. He will discuss the medications Depakote and Tegretol and their off-label uses in pediatric care in this presentation.
Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months: Ellen Mongan, M.D., Caroline Cahn, LCSW-C, Tom Flis, LCPC, Faith Dickerson, Ph.D., Robert Roca, M.D., Drew Pate, M.D., Meena Vimalananda, M.D., Briana Riemer, M.D. Ernestine Crosby, APRN, Darby Subotich, RN, MSN, Rick Wallace, RN, MSN, Jacqueline Williams-Porter, RN, MBA, Jennifer Tornabene, and Bonnie Katz.
Physician Statement: Sheppard Pratt Health System is accredited by The Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. Sheppard Pratt Health System designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Statement: Sheppard Pratt Health System is an approved provider of continuing nursing education by Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity is approved for 1.0 contact hours for nurses.
Psychologist Statement: Sheppard Pratt Health System is authorized by the State Board of Examiners of Psychologists as a sponsor of continuing education. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. Sheppard Pratt Health System designates this educational activity for a maximum of 1.0 CEU hours for Psychologists. Psychologists should claim credit commensurate with the extent of their participation in the activity.
Social Worker Statement: Sheppard Pratt Health System is authorized by the Board of Social Work Examiners of Maryland to offer continuing education for Social Workers. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity is approved for 1.0 CEU contact hours in Category 1 credits for Social Workers.
Counselor Statement: Sheppard Pratt Health System has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5098. Programs that do not qualify for NBCC credit are clearly identified. Sheppard Pratt Health System is solely responsible for all aspects of the program. This activity is available for 1.0 NBCC clock hours.
- 1.00 ACEP NBCC clock hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Category I credits for Social Workers
- 1.00 Psychologists
- 0.00 Participation